Fear clinical trials

Explore recruiting fear clinical trials.

Recruiting fear studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Fear trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

BOOSTCAMP - Boosting the endocannabinoid system before the treatment of anxiety symptoms

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Glucocorticoid enhancement of food exposure therapy in Binge Eating Disorder

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, triple-blind, placebo-controlled study on the effect of rifaximin on psychobiological functions in healthy men.

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.

Ireland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Experimental Study on Alcohol Use and Behavior in Young Adults

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

Targeted glucocorticoid administration to improve safety learning in posttraumatic stress disorder patients with HPA axis dysregulation

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

Fear trials by city

Fear in Toronto Fear in Vancouver Fear in Montreal Fear in Calgary Fear in Edmonton Fear in Ottawa Fear in Winnipeg Fear in Quebec City Fear in Hamilton Fear in Kitchener Fear in London Fear in Halifax Fear in New York Fear in Los Angeles Fear in Chicago Fear in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease